<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04154475</url>
  </required_header>
  <id_info>
    <org_study_id>DIPO 1.0</org_study_id>
    <nct_id>NCT04154475</nct_id>
  </id_info>
  <brief_title>Dairy Intervention in People With Obesity</brief_title>
  <acronym>DIPO</acronym>
  <official_title>Dairy Intervention in People With Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obesity is associated with increased morbidity and mortality, but weight reduction is
      difficult to achieve. In this randomized controlled trial we will include 120 obese subjects.
      Subjects will be allocated to one of the 3 diet types (minus 500 kcal / d):

        -  Yoghurt diet: 500 g low-fat yogurt / d, about 1000-1100 mg calcium / d,

        -  Milk product diet: 500 g of low-fat milk or buttermilk / d, about 1000-1100 mg calcium /
           d

        -  Standard diet: 500 g soy yogurt / d, about 500 mg calcium / d Primary endpoint is the
           change in fat mass (baseline vs. 12 weeks), secondary endpoints are metabolic and
           endocrine parameters, gut microbiome, quality of life, hunger and satiety.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>fat mass</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes in body fat mass assessed via dual-energy X-ray absorptiometry (DXA) (baseline vs. 12 weeks).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>12 weeks</time_frame>
    <description>body weight [kg]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI</measure>
    <time_frame>12 weeks</time_frame>
    <description>BMI [kg/m²]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>waist circumference</measure>
    <time_frame>12 weeks</time_frame>
    <description>waist circumference [cm]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hip circumference</measure>
    <time_frame>12 weeks</time_frame>
    <description>hip circumference [cm]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic blood pressure</measure>
    <time_frame>12 weeks</time_frame>
    <description>systolic blood pressure [mm Hg]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic blood pressure</measure>
    <time_frame>12 weeks</time_frame>
    <description>diastolic blood pressure [mm Hg]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition-lean mass</measure>
    <time_frame>12 weeks</time_frame>
    <description>lean mass [kg]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition-total body fat</measure>
    <time_frame>12 weeks</time_frame>
    <description>total body fat ([%]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition-gynoid fat mass</measure>
    <time_frame>12 weeks</time_frame>
    <description>gynoid fat mass [kg]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition-android fat mass</measure>
    <time_frame>12 weeks</time_frame>
    <description>android fat mass [kg]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCglucose</measure>
    <time_frame>12 weeks</time_frame>
    <description>Metabolic response during an oral glucose tolerance test (oGTT) as defined by AUCglucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinsulin</measure>
    <time_frame>12 weeks</time_frame>
    <description>Metabolic response during an oral glucose tolerance test (oGTT) as defined by AUCinsulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HOMA-IR</measure>
    <time_frame>12 weeks</time_frame>
    <description>Insulin resistance assessed by homeostatic model assessment-insulin resistance (HOMA-IR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HOMA-beta</measure>
    <time_frame>12 weeks</time_frame>
    <description>insulin sensitivity assessed by HOMA-beta</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MATSUDA</measure>
    <time_frame>12 weeks</time_frame>
    <description>insulin sensitivity assessed by MATSUDA-index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QUICKI</measure>
    <time_frame>12 weeks</time_frame>
    <description>insulin sensitivity assessed by Quantitative Insulin-sensitivity Check Index (QUICKI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total cholesterol</measure>
    <time_frame>12 weeks</time_frame>
    <description>Total cholesterol [mg/dl]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL cholesterol</measure>
    <time_frame>12 weeks</time_frame>
    <description>LDL cholesterol [mg/dl]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL cholesterol</measure>
    <time_frame>12 weeks</time_frame>
    <description>HDL cholesterol [mg/dl]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>12 weeks</time_frame>
    <description>Triglycerides [mg/dl]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>12 weeks</time_frame>
    <description>HbA1c [mmol/mol]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total testosterone</measure>
    <time_frame>12 weeks</time_frame>
    <description>Total testosterone [nmol/l]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Free testosterone</measure>
    <time_frame>12 weeks</time_frame>
    <description>Free testosterone [nmol/l]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Free androgen index</measure>
    <time_frame>12 weeks</time_frame>
    <description>FAI (Free androgen index)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>androstenedione</measure>
    <time_frame>12 weeks</time_frame>
    <description>androstenedione [nmol/l]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DHEAS</measure>
    <time_frame>12 weeks</time_frame>
    <description>dehydroepiandrosterone sulfate (DHEAS) [µmol/L]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stool microbiome</measure>
    <time_frame>12 weeks</time_frame>
    <description>Composition of the stool microbiome Microbiome analysis will be performed through the following steps: patient collection and provision of a stool specimen, DNA isolation from the specimen, PCR reaction to amplify the selected region of the 16S rRNA gene (only present in bacteria), sequencing of the amplicons using next-generation sequencing technology, bioinformatics processing and analysis of the data using suitable software.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satiety</measure>
    <time_frame>12 weeks</time_frame>
    <description>assessed via visual analogue scale [VAS]: &quot;Satiety&quot;, minimum score 0, maximum score 10, higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Food craving</measure>
    <time_frame>12 weeks</time_frame>
    <description>assessed via visual analogue scale [VAS]: &quot;Food craving&quot;, minimum score 0, maximum score 10, higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life during weight reduction</measure>
    <time_frame>12 weeks</time_frame>
    <description>Quality of life assessed via visual analogue scale [VAS]: &quot;How is your quality of life during weight reduction?&quot;, minimum score 0, maximum score 10, higher scores mean a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance</measure>
    <time_frame>12 weeks</time_frame>
    <description>assessed via visual analogue scale [VAS]: &quot;Compliance&quot;, minimum score 0, maximum score 10, higher scores mean a better outcome.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>yogurt diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>yogurt-diet (-500 kcal/day, 500 g yogurt, high calcium)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dairy diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>dairy diet: -500 kcal/day, high calcium, 500 g non-yogurt dairy products</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard diet: -500 kcal/day, low calcium, 500 g soya-yogurt</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>yogurt diet</intervention_name>
    <description>500 g yogurt/day</description>
    <arm_group_label>yogurt diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>dairy diet</intervention_name>
    <description>500 g non-yogurt dairy products</description>
    <arm_group_label>dairy diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>standard diet</intervention_name>
    <description>500 g soya-yogurt</description>
    <arm_group_label>standard diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI ≥30 kg/m²

          -  Age of ≥18 and &lt;60 years

          -  Written informed consent before study entry

          -  Willingness to introduce a dietary change to lose weight

        Exclusion Criteria:

          -  Serum calcium ≥2.7 mmol/l

          -  Dislike or intolerance of dairy products, reporting adverse responses or allergy to
             dairy products

          -  Pregnancy or lactating women

          -  Having given birth in the last year or planning a pregnancy in the next 6 months

          -  Menopause (as defined by FSH levels ≥30 IU/l)

          -  Disorders associated with androgen excess and/or menstrual irregularities except PCOS
             (overt thyroid dysfunction, hyperprolactinemia, adrenal hyperplasia, androgen
             secreting tumors)

          -  Malabsorption syndrome

          -  Intake of medication influencing metabolic or endocrine parameters (insulin
             sensitizers, oral contraceptives, …), obesity pharmacotherapeutic agents, or calcium
             supplements in the last 3 months before study entry

          -  Regular intake of calcium supplements in the last 3 months before study entry

          -  Lifestyle changes (changes in physical activity) or weight reduction (≥10% of body
             weight) in the last 3 months before study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elisabeth Lerchbaum, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elisabeth Lerchbaum, MD</last_name>
    <phone>0043 316 385 12383</phone>
    <email>elisabeth.lerchbaum@medunigraz.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University of Graz, Department of Internal Medicine, Division of Endocrinology and Metabolism</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 16, 2019</study_first_submitted>
  <study_first_submitted_qc>November 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2019</study_first_posted>
  <last_update_submitted>June 17, 2020</last_update_submitted>
  <last_update_submitted_qc>June 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>yogurt</keyword>
  <keyword>dairy</keyword>
  <keyword>calcium</keyword>
  <keyword>weight reduction</keyword>
  <keyword>obesity</keyword>
  <keyword>randomized controlled trial</keyword>
  <keyword>body composition</keyword>
  <keyword>microbiome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

